Traduction de «disorders as reaction » (Anglais → Français) :

To show that the Canadian government, the Government of Ontario, and other credible organizations agree that DDT, hexachlorobenzene, and other pesticides are carcinogens and cause other terrible illnesses, we have the following: a description from the Canadian Centre for Occupational Health and Safety, a federal government agency, of the harmful effects of DDT and benzene, including the fact that they are carcinogens; an article quoting Johanne Gélinas, the federal environment commissioner, to the effect that pesticides have been linked to lung disease, reproductive problems, birth defects, cancers, developmental disorders, allergic reactions ...[+++], lowered resistance to diseases, and other illnesses; an article from Ontario showing that Worker's Compensation and the occupational health clinics for Ontario agree that benzene, to which we were exposed, is a known carcinogen; a position paper for the Canadian Associationof Physicians for the Environment indicating the biological effects of DDT exposure; a recent release from the Ontario College of Family Physicians indicating that pesticides are too harmful to use in any form and that exposure to pesticides causes brain cancer, prostate cancer, kidney cancer, pancreatic cancer, and leukemia, among many other acute illnesses; and a list from OHIP that indicates the 53 different diseases and disorders with which I have been diagnosed in a seven-year period from 1987 to 1994 (1540) Further, to indicate that the Canadian army exposed troops to DDT, benzene hexacholoride, and other pesticides, I have the following: a copy of four pages from the Canadian Military Handbook of Army Health, issued in 1950, indicating that Canadian soldiers and their clothing should be sprayed with DDT and benzene hexacholoride, clearly indicating exposure; a letter from Paul Marsden, archivist for the military section of the government archives division, stating that DDT was used as a pesticide on soldiers while serving in Korea; a letter fro ...

Q-26 — Mr. Cummins (Delta—South Richmond) — With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the ...[+++] Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad sinc ...

[Text] Question No. 26 Mr. John Cummins: With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the La ...[+++]riam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad since 1 ...

That is to say, we need a virtuous policy, but at the same time we are now facing a particularly complex situation in that there are a series of professions who are in a very difficult position and which, as forms of Community-scale protests are developing in Europe, has lead to blockades and disorder and disparate reactions from our governments.

The Scientific Committee on Animal Health and Animal Welfare adopted on 10 March 1999 its report on animal welfare aspects of the use of bovine somatotrophin and stated that BST increases the risk of clinical mastitis as well as the duration of treatment of mastitis, it increases the incidence of foot and leg disorders and it can affect adversely reproduction and induce several severe reactions at the injection site.

The Scientific Committee on Animal Health and Animal Welfare adopted on 10 March 1999 its report on animal welfare aspects of the use of bovine somatotrophin and stated that BST increases the risk of clinical mastitis as well as the duration of treatment of mastitis, it increases the incidence of foot and leg disorders and it can affect adversely reproduction and induce several severe reactions at the injection site.